Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Opioid use is not associated with in-hospital mortality among patients with sickle cell disease in the United States
source: American Society of Hematology
year: 2018
authors: Oladimeji Akinola Akinboro, Stanley Nwabudike, Camille Edwards, Diana Cirstea, Nana Oduraa Addo-Tabiri, Michael Voisine, Hassan Yameen, Adetola A. Kassim
summary/abstract:Background:
Vaso-occlusive pain crises account for the majority of hospitalizations in patients with sickle cell disease (SCD), and opioids are the mainstay of chronic pain control in SCD.
The study sought to:
i) examine temporal trends in hospitalization rates and in-hospital mortality rates among adults with SCD
ii) compare in-hospital mortality rates for SCD with the rates of opioid prescription-related deaths in the non-SCD general population since the onset of the US opioid epidemic.
Method:
Data was obtained from the National Inpatient Sample from 1998 through 2013. Hospitalizations for patients with sickle cell disease were identified using discharge diagnoses. Hospitalization and in-hospital mortality rates and trends were examined for the entire sample of SCD patients, by the following age groups: 0-17 years, 18-44 years, 45-64 years, and >=65 years as well as by the U.S Census Bureau regions. Annual mid-year population figures provided by the US Census Bureau were used as the reference population for each year.
Result:
There were 1,755,220 hospitalizations among SCD patients in the US from 1998 to 2013. Hospitalization rates for SCD patients initially declined annually by 9.9% from 39/100,000 persons in 1998 to 27/100,000 persons in 2002, but no significant temporal trends were noted from 2002 to 2013. However, among young adults with SCD (18-44 years), there was a significant annual increase in hospitalization rates by 3.8% from 43/100,000 persons in 2002 to 71/100,000 persons in 2013. Elderly SCD patients (>=65 years) also had a significant annual increase in hospitalization rates by 6.5% from 2.7/100,000 persons in 1998 to 5.4/100,000 persons in 2013. The only region with a significant increase in SCD hospitalization rate was the South with an annual increase of 3.5% from 2001 through 2011. There was no significant increase in-hospital SCD mortality, in contrast to the 350% increase in non-SCD opioid prescription-related death rates in the US from 1999 through 2013.
Conclusion:
Hospitalization rates are rising among most age-groups of adults with SCD. The reasons for this finding are unclear but the rising rates may reflect the fragmentation of care for SCD in adults as well as age-related increases in pain-related comorbidities and SCD complications as SCD patients live longer. However, there has been no associated increase in-hospital SCD mortality, supporting extant data which suggest that the rate of opioid-related deaths in SCD is low, and the use of opioids for pain control may be considered relatively safe in the SCD population.
DOI: 10.1182/blood-2018-99-115573
read more
+myBinderRelated Content
-
Associations of Prolonged QTc in Sickle Cell DiseaseSudden death is a leading cause of morta...
-
The effects of pain-related anxiety on hypnosis treatment responses in adults with and without sickle cell diseasePain is the most common symptom in sickl...
-
A multiple drug approach to preventing sickle cell crisisSickle cell disease is characterized by ...
-
A Sickle Cell Warrior Survival Story— Timi Edwin“When I was 10, I was flogged by a tea...
-
APS Scientific Meeting 2019The American Pain Society will hold its ...
-
Vaso-Occlusive Pain Linked to Menstruation in Some Patients, Study FindsAcute vaso-occlusive pain is associated ...
-
Safety and early hints of benefit seen in phase 1b trial of PF-04447943Sickle cell disease (SCD) patients were ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.